Search Results - Paul M Kaye

Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates. by Sakshi Mohan, Paul Revill, Stefano Malvolti, Melissa Malhame, Mark Sculpher, Paul M Kaye

Connect to this object online.

Human leishmaniasis vaccines: Use cases, target population and potential global demand. by Stefano Malvolti, Melissa Malhame, Carsten F Mantel, Epke A Le Rutte, Paul M Kaye

Connect to this object online.

The potential impact of human visceral leishmaniasis vaccines on population incidence. by Epke A Le Rutte, Luc E Coffeng, Stefano Malvolti, Paul M Kaye, Sake J de Vlas

Connect to this object online.

Role of neutrophils in the pathogenesis of Post Kala-azar Dermal Leishmaniasis (PKDL). by Madhurima Roy, Ritika Sengupta, Bidhan Chandra Chakraborty, Uttara Chatterjee, Esther von Stebut, Paul M Kaye, Mitali Chatterjee

Connect to this object online.

Comparative expression profiling of Leishmania: modulation in gene expression between species and in different host genetic backgrounds. by Daniel P Depledge, Krystal J Evans, Alasdair C Ivens, Naveed Aziz, Asher Maroof, Paul M Kaye, Deborah F Smith

Connect to this object online.

Tegumentary leishmaniasis and coinfections other than HIV. by Dalila Y Martínez, Kristien Verdonck, Paul M Kaye, Vanessa Adaui, Katja Polman, Alejandro Llanos-Cuentas, Jean-Claude Dujardin, Marleen Boelaert

Connect to this object online.

M2 Polarization of Monocytes-Macrophages Is a Hallmark of Indian Post Kala-Azar Dermal Leishmaniasis. by Debanjan Mukhopadhyay, Shibabrata Mukherjee, Susmita Roy, Jane E Dalton, Sunanda Kundu, Avijit Sarkar, Nilay K Das, Paul M Kaye, Mitali Chatterjee

Connect to this object online.

Clinical anemia predicts dermal parasitism and reservoir infectiousness during progressive visceral leishmaniosis. by Max C Waugh, Karen I Cyndari, Tom J Lynch, Soomin Koh, Ferney Henao-Ceballos, Jacob J Oleson, Paul M Kaye, Christine A Petersen

Connect to this object online.

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. by Mohamed Osman, Anoop Mistry, Ada Keding, Rhian Gabe, Elizabeth Cook, Sarah Forrester, Rebecca Wiggins, Stefania Di Marco, Stefano Colloca, Loredana Siani, Riccardo Cortese, Deborah F Smith, Toni Aebischer, Paul M Kaye, Charles J Lacey

Connect to this object online.